Ineffective erythropoiesis in myelodysplastic syndromes: Correlation with fas expression but not with lack of erythropoietin receptor signal transduction

British Journal of Haematology

Volumn 106, Issue 2, 1999, Pages 464-473

  Fontenay Roupie, Michaëla ^a,b,c   Bouscary, Didier ^a,b   Guesnu, Martine ^a   Picard, Françoise ^a   Melle, Josiane ^a   Lacombe, Catherine ^a,b   Gisselbrecht, Sylvie ^b   Mayeux, Patrick ^b   Dreyfus, François ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSTITUT COCHIN   (France)

^c NONE   (France)

Author keywords

Apoptosis; Erythropoietin receptor; Fas; Myelodysplastic syndromes; STAT 5

Indexed keywords

ERYTHROPOIETIN RECEPTOR; FAS LIGAND; STAT5 PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CYTOPENIA; DNA BINDING; ERYTHROPOIESIS; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032863499     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01539.x     Document Type: Article

References (39)

1. Azam, M., Lee, C., Strehlow, I. & Schindler, C. (1997) Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity, 6, 691-701.
2. Backs, B., Broeders, L., Hoefsloot, L.H., Wognum, B. & Löwenberg, B. (1996) Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. Leukemia, 10, 466-472.
3. Backs, B., Broeders, L. & Löwenberg, B. (1992) Kit ligand rescue in vitro erythropoiesis in myelodysplastic syndromes. Blood, 80, 1213-1218.
4. Bouscary, D., de Vos, J., Guesnu, M., Jondeau, K., Viguier, F., Melle, J., Picard, F., Dreyfus, F. & Fontenay-Roupie, M. (1997) Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukaemia, 11, 839-845.
5. - sorted bone marrow cells of myelodysplasia patients. Blood, 88, 505-510.
6. Callus, B.A. & Mathey-Prevot, B. (1998) Interleukin-3-induced activation of the Jak/STAT pathway is prolonged by proteasome inhibitors. Blood, 91, 3182-3192.
7. Chretien, S., Varlet, P., Verdier, F., Gobert, S., Cartron, J.P., Gisselbrecht, S., Mayeux, P. & Lacombe, C. (1996) Erythropoietin-induced erythroid differentiation in the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO Journal, 15, 4174-4181.
8. Dai, C.H., Price. J.O., Brunner, T. & Krantz, S.B. (1998) Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by Interferon gamma to produce erythroid cells apoptosis. Blood, 91, 1235-1242.
9. Damen, J.E., Wakao, H., Miyajima, A., Krosl, J., Humphries, K.R., Cutler, R.L. & Kristal, G. (1995) Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and STAT5 activation. EMBO Journal, 14, 5557-5568.
10. Dumon, S., Constantino Rosa Santos, S., Debierre-Grockiego, F., Gouilleux-Gruart, V., Cocault, L., Boucheron, C., Mollat, P., Gisselbrecht, S. & Gouilleux, F. (1999) IL-3 dependent regulation of Bcl-XL gene expression by STAT5 in a bone marrow derived cell line. Oncogene (in press).
11. Dusanter-Fourt, I., Casadevall, N., Lacombe, C., Muller, O., Billat, C., Fischer, S. & Mayeux, P. (1992) Erythropoietin Induces the tyrosine phosphorylation of its own receptor in erythropoietin-responsive cells. Journal of Biological Chemistry. 267, 10670-10675.
12. Gersuk, G.M., Beckham, C., Loken, M.R., Kiener, P., Anderson, J.E., Farrand, A., Troutt, A.B., Ledbetter, J.A. & Deeg, H.J. (1998) A role for tumor necrosis factor-alpha. Fas and Fas-ligand in marrow failure associated with myclodysplatic syndrome. British Journal of Haematology, 103, 176-88.
13. Gobert, S., Chretien, S., Gouilleux, F., Muller, O., Pallard, C., Dusanter-Fourt, I., Groner, B., Lacombe, C., Gisselbrecht, S. & Mayeux, P. (1996) Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. EMBO Journal, 15, 2434-3441.
14. Gregoli, P.A. & Bondurant, M.C. (1997) The roles of Bcl-XL and apopain in the control of erythropoiesis by erythropoietin. Blood, 90, 630-640.
15. Gupta, P., Niehans, G.A., LeRoy, S.C., Gupta, K., Morrison, VA., Schultz, C., Knapp, D.J. & Kratzke, R.A. (1999) Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia, 13, 44-53.
16. Hoefsloot, L.H., van Amelsvoort, M.P., Broeders, L.C.A.M., van der das, D.C., van Lom, K., Hoogerbrugge, H., Touw, I.P. & Löwenberg, B. (1997) Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood, 89, 1690-1700.
17. Iwatsuki, K., Endo, T., Misawa, H., Yokouchi, M., Matsumoto, A., Ohtsubo, M., Mori, K.J. & Yoshimura, A. (1997) STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line. Journal of Biological Chemistry 272, 8149-8152.
18. Jeffers, M., Taylor, G.A., Wegner, K.M., Omura, S. & Van du Woude, G.F. (1997) Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Molecular and Cellular Biology, 17, 799-808.
19. Kitagawa, M., Saito, I., Kuwata, T., Yoshida, S., Yamaguchi, S., Takahashi, M., Tanizawa, T., Kamiyama, K. & Hirokawa, K. (1997) Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukaemia, 11, 2049-2054.
20. Klingmüller, U., Wu, H., Hsia, J.G., Toker, A., Duckworth, B.C., Cantley, L.C. & Lodish, H.F. (1997) Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proceedings of the National Academy of Sciences of the United States of America, 94, 3016-3021.
21. Koury, M.J. & Bondurant, M.C. (1990) Erythropoietin retards DNA breakdown and prevents programmmed cell death in erythroid progenitor cells. Science, 248, 378-381.
22. Krantz, S.B. (1991 ) Erythropoietin. Blood, 77, 419-434.
23. Lepelley, P., Grardel, N., Erny, O., Iaru, T., Obein, V., Cosson, A. & Fenaux, P. (1998) Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leukemia and Lymphoma, 30, 307-312.
24. + human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood, 85, 3183-3190.
25. Meyer, J., Jücker, M., Ostertag, W. & Stocking, C. (1998) Carboxyl-truncated STAT5β is generated by a nucleus-associated serine protease in early hematopoietic progenitors. Blood, 91, 1901-1908.
26. Mittelman, M., Gardyn, J., Carmel, M., Malovani, H., Barak, Y. & Nir, U. (1996) Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. Leukemia Research, 20, 459-466.
27. Mori, S., Tanaka, K., Omura, S. & Saito, Y. (1995) Degradation process of ligand-stimulated platelet-derived growth factor β-receptor involves ubiquitin-proteasome proteolytic pathway. Journal of Biological Chemistry. 270, 29447-29452.
28. Okada, M., Okamoto, T., Saheki, K., Fujimori, Y., Takemoto, Y. & Kakisita, E. (1997) Increased expression of Fas antigen and apoptosis in patients with myelodysplastic syndromes. Blood, 90, (Suppl. 1), 227a.
29. Parker, J.E., Fishlock, K.L., Mijovic, A., Pagliuca, A. & Mufti, G.J. (1997) Leukemic progression in myelodysplastic syndromes (MDS) is associated with decreased apoptosis and a reduced ratio of pro-versus anti-apoptotic Bcl-2 related proteins. Blood, 90, (Suppl. 1), 520a.
30. Parker, J.E. & Mufti, G.J. (1998) Ineffective haematopoiesis and apoptosis in myelodysplastic syndromes. British Journal of Haematology, 101, 220-230.
31. Rajapaksa, R., Ginzton, N., Rott, L.S. & Greenberg, P. (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88, 4275-4287.
32. Raza, A., Gezer, S., Mundle, S., Gao, X.Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney C., Showel, J., Gregory, S. & Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268-276.
33. Silva, M., Grillot, D., Benito, A., Richard, C., Nunez, G. & Fernandez-Luna, J.L. ( 1996) Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood, 88, 1576-1582.
34. Teglund, S., McKay, C., Schuetz, E., van Deursen, J.M., Stravopodis, D., Wang, D., Brown, M., Brodner, S., Grosveld, G. & Ihle, J.N. (1998) Stat5a and Stat5b proteins have essential and non-essential, or redundant, roles in cytokine responses. Cell, 93, 841-850.
35. Verdier, F., Chrétien, S., Muller, O., Varlet, P., Yoshimura, A., Gisselbrecht, S., Lacombe, C. & Mayeux, P. (1998) Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Journal of Biological Chemistry, 271, 28185-28190.
36. Witthuhn, B., Quelle, F.W., Silvennoinen, O., Yi, T., Tang, B., Miura, O. & Ihle, J.N. (1993) Jak2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell, 74, 227-236.
37. Wu, H., Klingmüller, U., Acurio, A., Hsiao, J.G. & Lodish, H.F. (1997) Functional interactions of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proceedings of the National Academy of Sciences of the United States of America, 94, 1806-1810.
38. Wu, H., Liu, X., Jaenisch, R. & Lodish, H.F. (1995) Generation of committed erythroid BFU-E and CFU-R progenitors does not require erythropoietin or the erythropoietin receptor. Cell, 83, 59-68.
39. Yu, C.L. & Burakoff, S.J. (1997) Involvement of proteasomes in regulating Jak-STAT pathways upon H,-2 stimulation. Journal of Biological Chemistry, 272, 14017-14020.